What is 10x Genomics, Inc.'s thereafter?

10x Genomics, Inc. (TXG) reported thereafter of $29.48M in Q1 2026.

How has 10x Genomics, Inc.'s thereafter changed year-over-year?

10x Genomics, Inc.'s thereafter increased by 11.9% year-over-year, from $26.34M to $29.48M.

Revenue$150.8M-2.6%

Gross profit$106.2M+0.7%

Operating income-$17.0M+56.7%

Net income-$13.5M+60.8%

EPS (diluted)-$0.10+64.3%

Cash & equivalents$490.3M+30.0%

Total debt$81.4M+1.6%

Total equity$814.3M+15.2%

Total assets$1.0B+12.4%

Operating cash flow$26.1M-24.0%

CapEx$1.6M-15.6%

Free cash flow$24.5M-24.4%

Market cap$4.41B+154%

Gross margin69.6%+1.2pp

Operating margin-6.1%-2.7pp

Net margin-3.5%-1.6pp

FCF margin19.1%—

Return on equity-3%-1.4pp

Debt / equity0.1×0.0×

Current ratio5.9×+0.5×

Reported directly by 10x Genomics, Inc. in its filing.

Tagged under the XBRL concept txg:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour.

The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

What is 10x Genomics, Inc.'s thereafter?: 10x Genomics, Inc. (TXG) reported thereafter of $29.48M in Q1 2026.
How has 10x Genomics, Inc.'s thereafter changed year-over-year?: 10x Genomics, Inc.'s thereafter increased by 11.9% year-over-year, from $26.34M to $29.48M.